01382nas a2200397   4500000000100000008004100001260001600042653001000058653001200068653004400080653002800124653002000152653001000172653002100182653002600203653001700229653001900246653001100265653001100276653002900287653001200316653000900328653001500337653001900352653003300371653001600404653001800420653003200438653002200470100001400492245007500506300000600581490000700587520037600594022001400970       2008                            d  c2008 Nov 1510aAdult10aAnimals10aAnti-Inflammatory Agents, Non-Steroidal10aAntifibrinolytic Agents10aBehcet Syndrome10aChild10aChild, Preschool10aGraft vs Host Disease10aHemorheology10aHIV Infections10aHumans10aInfant10aLeishmaniasis, Cutaneous10aleprosy10aMice10aMice, Nude10aPentoxifylline10aPhosphodiesterase Inhibitors10aSarcoidosis10aSkin Diseases10aTumor Necrosis Factor-alpha10aVascular Diseases1 aZargari O00aPentoxifylline: a drug with wide spectrum applications in dermatology.  a20 v143 a<p>Pentoxifylline (PTX) is a methylxanthine derivative with a variety of anti-inflammatory effects. Currently, PTX is approved by the Food and Drug Administration for the treatment of intermittent claudication, but studies have shown that it has a variety of physiological effects at the cellular level, which may be important in treating a diverse group of diseases.</p>  a1087-2108